Methods: This retrospective study covered the period from 2016 to 2021. The inclusion criteria were met as follow: 1. Hospitalized patients receiving cefepime; 2. eGFR greater than 60 mL/min/1.73 m2; 3. Age over 20. The outcomes included the length of hospital stay, duration of cefepime use, the change in CRP, and the change in WBC. Two-sample t test was performed.

Results and Discussion: There were 41 participants in each of the low-dose and non-low-dose groups, and 26 (63%) of them were males. The results of the efficacy comparison between the low-dose group and the non-low-dose group (represented by their respective mean values and p values): the mean length of hospital stay were 26.4 days, and 28.9 days (p=0.507), the mean use durations of cefepime were 7.4 days vs 6.2 days (p=0.238), the change in CRP were -1.3mg/dL, and -0.3mg/dL (p=0.216), and the change in WBC were 1000/mcL, and 860/mcL (p=0.888). The length of hospital stay were slightly lower in low-dose group, but the mean days of cefepime use were slightly higher than non-low-dose group. There was no statistical difference between two groups.

Conclusion: The efficacy of low-dose cefepime is similar to non-low-dose group in this study. But it is still necessary to carefully evaluate the efficacy of low-dose cefepime.